The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial by Marije F Bakker et al.
RESEARCH ARTICLE Open Access
The relation between cartilage biomarkers (C2C,
C1,2C, CS846, and CPII) and the long-term
outcome of rheumatoid arthritis patients within
the CAMERA trial
Marije F Bakker1*, Suzanne MM Verstappen1, Paco MJ Welsing1,2, Johannes WG Jacobs1, Zalima N Jahangier3,
Maaike J van der Veen4, Johannes WJ Bijlsma1 and Floris PJG Lafeber1 for
the Utrecht Arthritis Cohort study group
Abstract
Introduction: The aim of this study was to investigate whether serum biomarker levels of C2C, C1,2C, CS846, and
CPII can predict the long-term course of disease activity and radiographic progression early in the disease course
of rheumatoid arthritis (RA).
Methods: In patients in the CAMERA trial, levels of biomarkers were evaluated at baseline and after 1 year of
treatment. Relations of (changes in) biomarker values with the mean yearly radiographic progression rate and
mean disease activity over a 5-year period were evaluated by using regression analysis. The added predictive value
of biomarkers over established predictors for long-term outcome was analyzed by multiple linear regression
analysis.
Results: Of 133 patients, serum samples were available at baseline and after 1 year of treatment. In the regression
analysis C1,2C at baseline, the change in C2C, C1,2C, and the sum of the standardized changes in C2C + C1,2C
scores were statistically significantly associated with the mean yearly radiographic progression rate; the change in
CPII was associated with the mean disease activity over 5 years of treatment. In the multiple linear regression
analysis, only the change in C1,2C was of added predictive value (P = 0.004) for radiographic progression.
Explained variances of models for radiographic progression and disease activity were low (0.28 and 0.34,
respectively), and the biomarkers only marginally improved the explained variance.
Conclusions: The change in C1,2C in the first year after onset of RA has a small added predictive value for disease
severity over a 5-year period, but the predictive value of this biomarker combined with current predictive factors is
too small to be of use for individual patients.
Introduction
Biomarkers are molecules or fragments that are released
into biologic fluids during the process of tissue turnover
and, for rheumatoid arthritis (RA), are considered to be
indicative of degradation or synthesis of cartilage, bone,
and synovial tissue [1]. Several serum biomarkers are on
the market, including those provided by IBEX (Montreal,
Quebec, Canada); C2C, C1,2C, CS846, and CPII [2-5].
These biomarkers might be good candidates because they
directly reflect the bone and cartilage turnover rate in the
(affected) joints of patients with RA. The two markers for
collagen degradation originate from type II collagen (C2C)
and from type I as well as type II collagen (C1,2C), reflect-
ing cartilage and bone degradation. The marker for turn-
over originated from proteoglycan aggrecan (CS846) and
the marker for synthesis of type II procollagen (CPII).
Earlier research with these biomarkers showed no
consistent results regarding the predictive value for the
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long-term outcomes in (early) RA. Only six publications
described the relation of (one of) these biomarkers with
(long-term) radiographic (Table 1) or clinical (Table 2)
outcome in RA [6-11]. The relation between these bio-
marker values and radiographic progression is inconsis-
tent; some studies show a higher value in cases of
higher radiographic progression [7,9,11], whereas others
show a lower value in cases of higher radiographic pro-
gression [8] or show no association at all [7-11]. The
same holds true for the relation between these biomar-
ker values and disease activity over time [9].
Because of these conflicting results and the limited
available literature on the association between these bio-
markers and clinical and radiographic progression, the
aim of this study was to investigate whether values of
C2C, C1,2C, CS846, and CPII determined early in the
disease can predict the long-term radiographic and/or
clinical outcome in patients with early RA.
Materials and methods
Patients included in this study were participants in the
2-year randomized open-label prospective multicenter
treatment strategy trial (Computer Assisted Manage-
ment in Early Rheumatoid Arthritis, CAMERA) [12]. In
the CAMERA study, patients were randomly assigned to
either an intensive tightly controlled MTX-based
treatment strategy based on computer-guided monthly
predefined response criteria or to a conventional MTX-
based treatment strategy based on regular clinical prac-
tice with 3-monthly visits. All patients fulfilled the 1987
revised American College of Rheumatology (ACR) cri-
teria for RA [13]. At study entry, all patients had a dis-
ease duration of less than 1 year and were DMARD and
glucocorticoid naïve. The medical ethics committees of
all participating hospitals approved the study, and all
patients gave written informed consent before entering
the trial.
From all available patients, serum samples were col-
lected at baseline (before treatment) and 1 year after inclu-
sion into the study. Serum samples were frozen as soon as
possible after blood collection and stored at -20°C until
analysis (analysis shortly after all 1-year samples were
obtained). Because the trial was performed according to
general clinical practice as much as possible, sample col-
lection was not restricted to fasting conditions.
Biomarker analyses
For this study, only samples that had not been thawed
before were used. For all biomarkers, enzyme-linked
immunosorbent assays (ELISAs) were performed
according to manufacturer’s instructions (IBEX Mon-
treal, Quebec, Canada).
Table 1 Overview of the literature on the (significant) relation between biomarker and radiographic progression
Author Population No. Biomarker Classification Results
Syversen et
al.10
RA ≤4 yr 136 C2C (baseline serum) SHS rapid >1 vs. slow <1 NS
(radiographic progression per yr, progression change
baseline to 5 or 10 yr)
Mullan et al.9 RA 45 C2C (baseline,1, 3, 6, 9,12-
mo serum)
C2C ↑ at 1, 3 mo




CPII (radiographic progression at 1 yr) NS
ΔCOL (ΔC2C + ΔC1,2C +
ΔCPII)




RA ≤1 yr 87 C2C (1, 2, 3, 4-yr serum) C2C ↑
C1,2C 66th = SHS >7.4 vs. 33rd percentile = SHS <2.3 C1,2C ↑




RA 63 C2C (knee SF) Mild vs. moderate vs. severe RA NS
(mean 10 yr) CS846 Mild vs. moderate RA CS846 ↓
CPII Mild vs. moderate vs. severe RA NS
(Larsen score: 0, 1 = mild; 2, 3 = moderate; 4, 5 = severe)
Mansson et
al.8
RA ≤2 yr 18 CS846 (baseline serum) Rapid vs. slow hip-joint radiographic progression CS846 ↓
CPII (Larsen score: rapid = 46; slow = 4 at 2 yr) NS
Number, number of patients investigated in the studies; DAS28, disease activity score based on 28 joints; mo, month; NS, not significant. PsA, psoriatic arthritis;
RA, rheumatoid arthritis; SF, synovial fluid; SHS, SharpvanderHeijde score; yr, year.
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The C2C serum ELISA detects a cartilage-specific col-
lagen type II collagenase cleavage neoepitope [2]. The
C1,2C ELISA detects a collagenase generated collagen
type I and II cleavage neoepitope [3]. The CS846 ELISA
detects an epitope on chondroitin sulfate of newly
formed large aggrecan molecules [4]. The CPII ELISA
recognizes epitopes of the propeptide of collagen type II
reflecting synthesis [5].
Values of all four biomarkers were log transformed to
obtain normal distributions. Additionally, seven extreme
data point outliers derived from C2C, CS846, and CPII
(based on visual inspection) were excluded for analysis.
(Long-term) outcome measurements
The long-term outcome of RA patients was determined by
the radiographic joint progression and by the mean disease
activity over a 5-year period of treatment. To assess radio-
graphic joint progression, radiographs of hand and feet
were made at baseline and every subsequent year. Radio-
graphs were independently scored according to the Sharp-
vanderHeijde score (SHS) [14] by two readers, blinded to
clinical information. The mean yearly radiographic pro-
gression rate between baseline and 5 years was used as the
outcome measure. For this rate, if 5-year radiographs were
not available, the mean of the measurements between 4
and 6 years was used, or scores at 4 or 6 years, depending
on the data available. Because scores were not normally
distributed, the log-transformed progression rate (log rate
+1) was used.
The mean disease activity over a 5-year period was
determined by calculating a time-averaged value of the
DAS28 [15] by using the area under the curve (AUC)
from baseline until 5 years after treatment. If more than
two yearly time points were missing, no time-averaged
DAS28 could be calculated.
The early response has been shown to be a predictor for
long-term outcome [16] and was therefore also taken into
account in the analysis. The DAS28 at baseline and 6
months was used to calculate the early EULAR response.
Patients were classified as good, moderate, or nonrespon-
ders based on their early (change in) disease activity. Good
responders should have a DAS28 score ≤3.2 at 6 months
and an improvement from baseline >1.2; nonresponders a
DAS28 score >5.1 and an improvement between 0.6 and
1.2 or only an improvement of ≤0.6. Patients with moder-
ate response had a response in between the good respon-
ders and the nonresponders.
Statistical analyses
The change in biomarker values was calculated by sub-
tracting the baseline biomarker value from the 1-year
value for all biomarkers. Furthermore, sum scores of
(changes in) markers representing synthesis (CS846 and
CPII) and sum scores of (changes in) markers for degra-
dation (C2C and C1,2C) were calculated. Finally, the
ratio of (the sum scores of) synthesis and degradation
markers were calculated. Because ranges of individual
biomarker values differ, Z-scores (calculated by subtract-
ing the average value from the individual value divided
by the standard deviation) were used for the sum and
ratio scores.
The relation between the individual (change, sum, and
ratio of) biomarker values and long-term outcome (that
is, mean yearly radiographic progression rate and time-
averaged DAS28) was investigated by linear regression
analysis, adjusting for the treatment strategy (that is,
intensive tightly controlled or conventional MTX-based
strategy).
Second, to investigate whether biomarker values were
of additional value over already known baseline
Table 2 Overview of the literature on the (significant) relation between biomarker and the disease activity
Author Population No. Biomarker Classification Results
Mullan et
al.9
RA 45 C2C (baseline,1, 3, 6, 9,12-
mo serum)
DAS28 responders vs. nonresponders (at 3 mo) C2C ↓
PsA 17 C1,2C (responder: ≥0.6 improvement and DAS28 ≤5.1, nonresponder: <0.6










RA 45 C2C (baseline,1, 3, 6, 9,
12-mo serum)
C2C ↓ at 1 mo
PsA 17 C1,2C Remission vs. no remission C1,2C ↓ at 1
mo
(mean, 11 yr, CPII (remission = DAS28 <2.6 at 6 mo) NS




DAS28, disease activity score based on 28 joints; mo, month; NS, not significant; number, number of patients investigated in the studies; PsA, psoriatic arthritis;
RA, rheumatoid arthritis; SF, synovial fluid; yr, year.
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predictors (rheumatoid factor (RF) and joint damage or
disease activity at baseline, respectively), multiple linear
regression analysis was used, adjusting for treatment
strategy. The sum and ratio scores were considered in
the analysis only when the individual biomarkers had a
significant association with the outcome in the initial
analysis. In the final model also, the early (6-month)
EULAR response was added, by means of two dummy
variables (good and moderate response, with nonre-
sponse as the reference category).
The statistical software SPSS 15.0 was used for the
analyses. A P value < 0.05 was considered statistically
significant.
Results
Of 133 patients in the CAMERA trial, unthawed serum
samples were available at baseline and at 1 year of treat-
ment. Of these patients, 75 had been treated according
to an intensive, tightly controlled MTX-based strategy,
and 58 patients according to a conventional MTX-based
strategy. For five patients, no mean yearly radiographic
progression rate could be calculated because of missing
scores. For 11 patients, no time-averaged DAS28 could
be calculated because more than two DAS28 scores
were missing. Baseline characteristics of patients with
missing data were not statistically significantly different
from those of patients with complete data. Clinical char-
acteristics and biomarker data of the patients are shown
in Table 3. Note that radiographic progression is limited
(median (IQR) radiographic progression rate over 5
years is 1.0 (0.0 to 3.4); mean (SD) value, 2.7 (4.5) SHS
units).
In the analyses correcting for treatment strategy,
C1,2C at baseline, the change in C2C and in C1,2C, and
(consequently) the sum of the standardized changes in
C2C + C1,2C levels were statistically significantly related
to the mean yearly radiographic progression rate (all P <
0.05; Table 4). Only the change in CPII levels was
related to time-averaged DAS28 (P = 0.03; Table 4).
In the multiple linear regression analyses, the change
in C1,2C and the sum of the standardized changes in
C2C + C1,2C levels were significantly related (P = 0.004
and P = 0.02, respectively) to mean yearly radiographic
progression rate in addition to RF, baseline joint
damage, and early (6-month) EULAR response. How-
ever, when including both changes in biomarkers values
in the analysis, they were no longer statistically signifi-
cant (P = 0.13 and P = 0.94, respectively). The change
in C1,2C was chosen for the final model because this
biomarker had the highest standardized beta, and the
final model had the highest R2 when compared with the
sum of the standardized changes in C2C + C1,2C levels;
furthermore, including only one biomarker instead of
two is more efficient.
The R2 of the final model increased from 0.23 without
biomarker to 0.28 including the change score of C1,2C
(Table 5). When early response was not included, results
were comparable, and the R2 of the model changed from
0.20 to 0.27 if C1,2C was added. The standardized beta
values showed that the influence of the biomarkers on
prediction of the mean yearly radiographic progression
rate was much smaller than, for instance, the predictive
influence of baseline joint damage (standardized beta =
-0.24 vs. 0.44, respectively; Table 5).
The change score of CPII was not statistically signifi-
cantly related (P = 0.18) to time-averaged DAS28. The
R2 of the model increased marginally from 0.32 without
biomarker to 0.34 including this biomarker (Table 6).
When early response was not included in the model, the
R2 increased from 0.13 to 0.21 by adding the biomarker,
but CPII was still not statistically significantly related to
time-averaged DAS28. The standardized beta values also
showed that the influence of the biomarkers was much
smaller than those of RF, baseline disease activity, and
early EULAR response (Table 6).
Discussion
The results show that some of the biomarkers have a
small predictive value for long-term outcome in early
RA, but clearly less, compared with established
Table 3 Clinical and biomarker characteristics obtained at
baseline and follow-up of all available patients
Characteristic No. = 133
Female gender (%) 87 (65)
Age (years) 53 (14)
RF positivity (%) 87 (65)
Baseline DAS28 5.6 (1.0)
Baseline joint damage 0.0 (0.0-0.0)
EULAR good responders (%) 50 (38)
EULAR moderate responders (%) 58 (44)
EULAR no responders (%) 24 (18)
Time-averaged DAS28 3.0 (0.9)
Radiographic progression rate 1.0 (0.0-3.4)
C2C (ng/ml) Baseline 90 (71-124)
1 yr 86 (70-109)
C1,2C (ng/ml) Baseline 359 (286-427)
1 yr 349 (269-415)
CS846 (ng/ml) Baseline 100 (68-155)
1 yr 113 (69-183)
CPII (ng/ml) Baseline 335 (207-551)
1 yr 436 (220-613)
Mean (SD) is shown for age and (baseline and time-averaged) DAS28; median
(IQR) is shown for all other (non-normally distributed) continuous variables.
For all categoric variables, number (%) of patients is shown. The EULAR
response was determined after 6 months of treatment; time-averaged DAS28
and radiographic progression rate were calculated over 5 years of treatment;
all other variables were determined at baseline unless otherwise stated. RF,
rheumatoid factor; DAS28, disease activity score based on 28 joints.
Bakker et al. Arthritis Research & Therapy 2011, 13:R70
http://arthritis-research.com/content/13/3/R70
Page 4 of 8
predictors. Only the change in C1,2C, the sum of the
standardized changes in C2C + C1,2C levels, and the
change in CPII were of added value for the mean yearly
radiographic progression rate and the time-averaged
DAS28, respectively. However, the explained variance of
the final prediction models was low and therefore not
useful for clinical practice, and both biomarkers
increased the explained variance only marginally (and
not statistically significantly for CPII).
Possible explanations for not finding a relation with all
biomarkers are multiple. Importantly, it should be con-
sidered that blood for serum was collected during the
day, which will influence the biomarker levels [17]. With
respect to changes in biomarkers, it might have been
worthwhile to evaluate changes in biomarkers within a
shorter time span (for example, 3 or 6 months from base-
line). However, no biologic samples were available at
these time points. Also of relevance are the small
variances in outcome regarding the radiographic progres-
sion due to the low radiographic scores, despite the 5
years of follow-up. We compared other investigations of
the four biomarkers (see Tables 1 and 2) with our own
data; patients in the other studies had higher radio-
graphic scores at baseline and had, on average, also
higher disease durations (varying from 1 to 10 years RA).
The available radiographic scores at baseline of the evalu-
ated studies range from 6.8 to 60 for SHS (mean) and 2
to 7 for the Larsen score (median) compared with 0 SHS
(median) in our study. Verstappen et al. [11] investigated
the same biomarkers comparing fast (>7.3 SHS units/
year) and slow progressors (<2.3 SHS units/year) and
found significant differences in biomarkers values, except
for CPII, in another cohort of patients with early RA.
However, these slowest progressors (calculated over a
4-year period) in this previous study are comparable to
the patients with the fastest progression (66th tertile >2.4
Table 4 Association between biomarker values and the long-term outcome measures
Long-term outcome (5 years after treatment)
Yearly radiographic progression rate Time-averaged DAS28
Biomarker No. B 95% CI No. B 95% CI
C2C Baseline 126 0.08 -0.28 to 0.44 120 0.11 -0.25 to 0.47
1 yr 126 -0.23 -0.67 to 0.20 120 0.18 -0.25 to 0.61
Change 126 -0.59 -1.14 to -0.03 120 0.04 -0.52 to 0.60
C1,2C Baseline 126 0.47 0.001 to 0.95 120 0.10 -0.40 to 0.60
1 yr 127 0.14 -0.36 to 0.65 121 0.22 -0.29 to 0.73
Change 126 -1.00 -1.80 to -0.20 120 0.33 -0.52 to 1.18
CS846 Baseline 127 -0.06 -0.27 to 0.16 121 -0.08 -0.29 to 0.14
1 yr 126 -0.07 -0.29 to 0.15 120 -0.03 -0.26 to 0.20
Change 126 -0.01 -0.23 to 0.21 120 0.05 -0.18 to 0.28
CPII Baseline 124 0.14 -0.07 to 0.35 118 -0.05 -0.26 to 0.17
1 yr 125 0.13 -0.09 to 0.34 119 0.10 -0.12 to 0.31
Change 122 -0.07 -0.34 to 0.20 122 0.30 0.02 to 0.57
ZC2C + ZC1,2C Baseline 125 0.07 -0.02 to 0.17
1 yr 126 0.01 -0.11 to 0.08
Change 126 -0.13 -0.22 to -0.04
Biomarkers with B (95% confidence interval (CI)) values, which are shown in Bold type have a P value < 0.05 and have been included in the multiple regression
analyses. Biomarkers values were determined at baseline, at 1 year, and the change between 1 year and baseline. Next are the sum and ratio scores (based on Z-
values), determined when individual biomarkers had a significant association with the outcome in the initial analysis.
DAS28, disease activity score based on 28 joints; n, number of patients investigated; 95% CI, 95% confidence interval.
Table 5 Added predictive value of biomarkers over already known predictors for mean yearly radiographic
progression rate over 5 years of treatment
Item B 95% CI Standardized beta P R2
Intercept 0.54 0.12 to 0.96 0.013
Treatment strategy 0.13 -0.16 to 0.43 0.08 0.375 0.000
RF positive 0.29 -0.02 to 0.60 0.15 0.063 0.029
Baseline joint damage 0.09 0.06 to 0.13 0.44 0.000 0.211
EULAR good responsea -0.36 -0.78 to 0.07 -0.20 0.100
EULAR moderate responsea -0.13 -0.52 to 0.27 -0.07 0.534 0.229
C1,2C change from 1 yr to baseline -1.11 -1.87 to -0.36 -0.24 0.004 0.283
aEULAR nonresponse was used as reference category. 95% CI, 95% confidence interval; RF, rheumatoid factor.
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SHS units/year) in our present study (calculated over a 5-
year period). Important to consider is that, because of
improved treatment (strategies), the progression rate
now in the Western community will hardly exceed the
progression rate of the present cohort. This progress in
treatment effectiveness and tight control strategies titrat-
ing treatment to the disease course of an individual
patient might counterbalance the predictive value of bio-
markers in prediction of disease outcome. However, it
should not be ignored that also in the previous studies
with higher radiographic progression rates, the relation
of these biomarkers with outcome was not straightfor-
ward (see Table 1).
In a post hoc analysis evaluating all sum and ratio
scores of synthesis and degradation markers (instead of
only the ones when the individual biomarker had a sig-
nificant association), no significant associations were
seen with both the mean yearly radiographic progression
rate and the time-averaged DAS28 over a 5-year period
of treatment; this also applied for the multiple linear
regression analysis (data not shown). The possible influ-
ence of age and gender on the biomarker values was
also investigated with multiple linear regression analyses;
adding these variables to the models did not change the
results (data not shown). Using logistic regression analy-
sis comparing progressors versus nonprogressors in
radiographic progression (any radiographic damage at 5
years) also did not change the results (data not shown).
When patients were selected with a minimum radio-
graphic progression rate of 1 point per year (SHS of 5
units at 5 years), the relation with the biomarkers did
not improve (data not shown). In case progression in
joint space narrowing and erosions were taken apart,
because biomarkers primarily represent cartilage turn-
over, no significant relations with biomarkers were
found (data not shown).
Although glucocorticosteroid (GC) use was prohibited
during the 2-year trial period; after 2 years, GC use was
free. Only a limited number of patients used GC (n =
13). Because GC may influence joint damage signifi-
cantly [18], analyses were performed in the group of
patients not using GC during the 5 years of treatment.
In these post hoc analyses, no clear relations between
radiographic joint damage and biomarkers were found.
The direction of the relation between the biomarkers
and the mean yearly radiographic progression rate and
time-averaged DAS28 was not anticipated. An increase
in C1,2C during 1 year of treatment, which indicates
more connective tissue degradation, led to lower mean
yearly radiographic progression rate, whereas a higher
time-averaged DAS28 was reached with an increase in
cartilage collagen synthesis, as determined by an
increase in CPII between baseline and 1 year of treat-
ment. Conversely, in vitro data reveal that the neoepi-
tope can increase when collagenase activity is blocked
[19]. This is because collagenase can cleave the neoepi-
tope that it generates [3]. In osteoarthritis (OA) serum,
CPII increased with progression of OA (Poole et al.,
unpublished data), similar to that in the present study
on RA. As in general, contrasting relations have been
found (Tables 1 and 2 and this study), clearly the nat-
ure, origin, and metabolism of these (and other) biomar-
kers require further investigation [20].
Based on the present results, the investigated markers
are not the first choice in predicting long-term outcome
in individual patients with early RA. The available studies
together with the present results suggest that the role of
these markers in predicting long-term outcome is at
most modest. They might, conversely, be of value for
other joint diseases or in distinguishing RA from other
arthritis conditions. Significant differences in these bio-
markers were reported when comparing RA with psoria-
tic arthritis [6], OA [6,7], and controls [8]. When we
investigated the baseline biomarker values of the early
RA patients of the CAMERA trial with controls, also sig-
nificant differences were seen (all P < 0.01; data not
shown). For assessment of progression in treatment with
anti-TNF, these biomarkers appeared of use [9].
Biomarkers in general might be of value in prediction
of the long-term outcome of RA. CTX-II [21-25], CTX-
I [22,24], MMP-3 [25,26], COMP [27], calprotectin [28],
RANKL [29,30], and IL-6 [31] all had a relation with
Table 6 Added predictive value of biomarkers over already known predictors for time-averaged disease activity
(DAS28) over 5 years of treatment
Item B 95% CI Standardized beta P R2
Intercept 1.90 0.99 to 2.81 0.000
Treatment strategy -0.29 -0.62 to 0.03 -0.16 0.076 0.076
RF positive 0.35 0.02 to 0.68 0.18 0.040 0.098
Baseline disease activity 0.25 0.10 to 0.40 0.30 0.001 0.169
EULAR good response -0.84 -1.30 to -0.37 -0.46 0.001
EULAR moderate response -0.19 -0.64 to 0.25 -0.11 0.393 0.322
CPII change 1 yr to baseline 0.18 -0.08 to 0.43 0.12 0.178 0.335
EULAR nonresponse was used as reference category. 95% CI, 95% confidence interval; RF, rheumatoid factor.
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(long-term) radiographic progression and/or the disease-
activity score. Of all these biomarkers, urinary CTX-II is
at present the most frequently used and best-performing
marker. Recently, a trial demonstrated urinary CTX-II
and DAS28 almost equally effective when used to moni-
tor disease activity and in treatment decisions aiming at
remission of disease of RA [32]. Unfortunately, in our
study, no urine samples were obtained.
Conclusions
In conclusion, the change in C1,2C and CPII in the first
year after onset have a small added predictive value for
radiographic progression and disease activity, respec-
tively, over a 5-year period, although the predictive
value is too small to be useful in daily clinical practice.
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